Misyo (Methadone Hydrochloride)

Methadone acts as a full agonist at the mu‑opioid receptor, delivering analgesic effects and suppressing opioid withdrawal. In addition, it blocks NMDA receptors, which can lessen the development of tolerance and modulate certain types of neuropathic pain, resulting in a sustained therapeutic effect.

The appropriate dose of Misyo is individualized by the prescribing clinician based on factors such as the patient’s opioid tolerance, the severity of pain or dependence, liver function, and any concurrent medications. Dosage adjustments are made during treatment to achieve optimal control while minimizing adverse effects.

Safety data for methadone use in pregnancy and lactation are limited. While methadone is sometimes used in opioid‑dependent pregnant women under strict medical supervision, potential risks to the fetus or infant exist. Breastfeeding while on methadone should only be considered after a risk‑benefit assessment by a qualified healthcare professional.

To order Misyo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature requirements) and the necessary import documentation.

The primary alternative for opioid dependence is buprenorphine, a partial mu‑opioid agonist with a ceiling effect on respiratory depression. Methadone, as a full agonist, offers more potent analgesia and may be preferred for patients requiring higher opioid coverage, but it carries a greater risk of respiratory depression and requires stricter monitoring.

Misyo should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store it in bathrooms or near heat sources. No special refrigeration is required for this oral formulation.

Misyo is administered orally, usually as a tablet or liquid taken with water. The exact route (swallow whole or dissolve) depends on the specific dosage form supplied. Patients should follow the prescriber’s instructions regarding timing, food intake, and whether the dose should be taken with or without meals.

The most serious risks associated with Misyo include respiratory depression, especially when combined with other CNS depressants, and cardiac arrhythmias due to QT interval prolongation. Patients should be educated to seek immediate medical attention if they experience shallow breathing, severe dizziness, palpitations, or any signs of an allergic reaction.

Misyo is contraindicated in individuals with known hypersensitivity to methadone or any component of the formulation, in patients with acute respiratory insufficiency, and in those taking monoamine oxidase inhibitors within 14 days. Caution is also advised for patients with severe hepatic impairment, uncontrolled cardiac disease, or a history of severe opioid addiction without supervised treatment.